KRAS is a critical oncogene involved in various cancers, including lung, colorectal, and pancreatic cancers. It encodes a protein that controls key cell signaling pathways essential for cell growth and survival. Mutations in KRAS lead to its constant activation, driving tumor development. Targeting KRAS has been difficult due to the lack of clear binding sites. However, significant progress has been made in designing inhibitors that specifically target the mutated KRAS protein. Researchers are focusing on small molecules and other innovative approaches to block KRAS function, aiming to overcome resistance mechanisms and provide new therapeutic options for cancer patients.